[A25-54] Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2025
Project no.:
A25-54
Commission:
Commission awarded on 28.04.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment
Zusatznutzen nicht belegt
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-54
| Project no. | Title | Status |
|---|---|---|
| A22-80 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-81 | Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-07 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-08 | Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-115 | Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |